New malaria pill tested in humans for first time

NCT ID NCT06171113

Completed Knowledge-focused Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug called GSK4024484 in 156 healthy adults to see if it is safe and how the body handles it. Researchers will also check if food affects the drug. The goal is to gather safety information before testing it in people with malaria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK4024484
What this could lead to: If this early study shows the drug is safe, it could lead to larger trials testing whether GSK4024484 can treat or prevent malaria.
What could go wrong: This is a very early Phase 1 trial in healthy people, not patients. The drug may prove unsafe or ineffective in later studies. Side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA,FALCIPARUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA,FALCIPARUM

Contacts and locations

Locations

GSK Investigational Site

Cambridge, CB2 0GG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.